Mangrove Partners
DMAA icon

Mangrove Partners’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Mangrove Partners’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-350,000
Closed -$3.57M – 254
2025
Q2 		$3.57M Hold
350,000
– – 0.38% 44
2025
Q1 		$3.51M Buy
+350,000
New +$3.5M 0.38% 47

Other funds holding DMAA

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Westchester Capital Management (New York)
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Mizuho Securities USA
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mangrove Partners's DMAA Position: Q3 2025 in Review

Mangrove Partners sold out of Drugs Made In America Acquisition Corp (DMAA) in Q3 2025, closing a stake of 350,000 shares — an estimated $3.57M sold.

Mangrove Partners first reported a position in DMAA in Q1 2025 and held it in 2 quarters. The position peaked at $3.57M in Q2 2025. 37 funds tracked by Wall St. Rank hold DMAA as of Q3 2025.

  • Mangrove Partners reported no remaining Drugs Made In America Acquisition Corp position as of Q3 2025 after selling out during the quarter.
  • Mangrove Partners sold 350,000 Drugs Made In America Acquisition Corp shares in Q3 2025, an estimated $3.57M.
  • Mangrove Partners first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 2 quarters.
  • Mangrove Partners's Drugs Made In America Acquisition Corp position peaked at $3.57M in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2025.

Based on Mangrove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.